- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04156087
Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)
Progression-free Survival After Minimally Invasive Surgical Microwave Ablation Plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer: MIMIPAC Trial
Study Overview
Status
Conditions
Detailed Description
Research Hypothesis Does MIS-MWA combined with durvalumab (MEDI4736) plus tremelimumab and gemcitabine prolong progression-free survival in patients with unresectable non-metastatic adenocarcinoma of the pancreas?
Investigational Product(s) and Reference Therapy:
Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.
Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.
Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Objectives:
Primary Objectives:
Progression-free survival (PFS)
Secondary Objectives:
- Safety: clinical and hematological toxicity (NCI CTCAE v. 5.0) of chemotherapy and immunotherapy
- Safety: number and type of postoperative complications of the MIS-MWA procedure
- Length of hospital stay
Tertiary Objectives Overall survival (OS)
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- University Hospitals KU Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with unresectable non-metastatic Locally Advanced Pancreatic Cancer (LAPC) defined according to NCCN guidelines Version 2.2017
- Histologically proven adenocarcinoma of the pancreas located in the head, body or tail
- LAPC tumor greatest diameter maximum 5 cm
- Male or female, age 18 years and older, ECOG PS 0-1
- Life expectancy of at least 12 weeks
- Only patients who did not receive chemotherapy for their PC are allowed
- Patients without distant organ metastases on conventional diagnostic imaging
- Pre-operative biliary drainage for obstructive jaundice is allowed, but the type of biliary stent is standardized in all jaundiced patients
- Patients fit for MIS-MWA
- Able to receive Durvalumab and Tremelimumab.
- Patients with good liver and renal function and with good hematology
- Effective contraception for both male and female patients if applicable. Women of childbearing potential must have negative blood pregnancy test at screening visit.
- Written informed consent (+ optional for TR) must be given according to ICH/GCP and national/European regulations
Exclusion Criteria:
- Pregnancy
- Metastatic PC on conventional diagnostic imaging or staging laparoscopy
- LAPC tumor greatest diameter is larger than 5 cm
- Borderline or resectable PC defined according to the NCCN guidelines version 2.2017
- Systemic chemo(radio)therapy is not allowed before MIS-MWA
- Major surgical procedure within 28 days prior to the first dose of investigational products
- Classic contraindications for PDL and CTLA antibodies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MIMIPAC
Intervention: MIS-MWA plus immunotherapy using the combination of durvalumab with tremelimumab
|
Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery. Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression. Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Other Names:
Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery. Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression. Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest. Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery. Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression. Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest.
Other Names:
Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 12 months
|
The study is exploratory and cannot be statistically powered for comparisons.
Median progression-free survival (PFS) time is chosen as the clinically meaningful outcome.
Survival estimates will be calculated using the Kaplan-Meier method.
For information, the reference PFS time in patients with non-metastatic LAPC treated with gemcitabine monotherapy is about 6 months.
Results will be presented descriptively.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Baki Topal, MD, UZ Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Durvalumab
- Tremelimumab
- Gemcitabine
Other Study ID Numbers
- UZ S61508
- 2018-002852-34 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer Non-resectable
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Asan Medical CenterRecruitingPancreatic Adenocarcinoma | Pancreatic Cancer Non-resectableKorea, Republic of
-
Rise Biopharmaceuticals, Inc.T-TOP Clinical Research Co., Ltd.RecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectableTaiwan
-
University of OxfordNational Institute for Health Research, United Kingdom; ImunonWithdrawnPancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectableUnited Kingdom
-
Health Science Center of Xi'an Jiaotong UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...Not yet recruitingPancreatic Cancer Non-resectable
-
University of LouisvilleJames Graham Brown Cancer CenterCompletedPancreatic Cancer Non-resectableUnited States
-
Immunitor LLCUnknownPancreatic Cancer Non-resectableMongolia
-
Shanghai Proton and Heavy Ion CenterRecruitingPancreatic Cancer Non-resectableChina
Clinical Trials on Durvalumab 50 MG/ML
-
University of CologneAstraZenecaRecruiting
-
University of NebraskaAstraZenecaRecruitingLung Cancer | Carcinoma, Non-Small Cell LungUnited States
-
University Hospital MuensterVifor PharmaTerminatedAnemia | Orthopedic Surgery | High Risk of Blood LossGermany
-
Lawson Health Research InstituteCompletedPostoperative Air LeakCanada
-
Biosynexus IncorporatedCompletedStaphylococcal SepsisUnited States
-
Adapt Produtos Oftalmológicos Ltda.WithdrawnOcular Hypertension | Open Angle GlaucomaBrazil
-
PfizerCompleted
-
Bausch Health Americas, Inc.Completed
-
Rare Disease Research, LLCSarepta Therapeutics, Inc.TerminatedDuchenne Muscular DystrophyUnited States
-
Bausch Health Americas, Inc.Withdrawn